Compare Summit Therapeutics Inc (SMMT) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs US Bancorp — how do they compare? Summit Therapeutics Inc trades at $15.19 (market cap $12.06B), while US Bancorp trades at $64.77 (market cap $100.17B). The key difference: US Bancorp is far larger — about 8.3× Summit Therapeutics Inc's market cap, and US Bancorp pays a 3.24% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | USB | |
|---|---|---|
Market Cap | $12.06B | $100.17B |
Sector | Health | Financials |
52-Week High | $26.98 | $64.47 |
52-Week Low | $12.55 | $45.28 |
Enterprise Value | $11.39B | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
U.S. Bancorp (USB) trades at $64.80, up 0.95% today, with a bullish technical trend and strong support at $64. The company reported Q2 2026 EPS of $1.35, beating estimates, and maintains a net income margin of 27.61%. Recent news highlights institutional buying and upbeat Q2 results, reinforcing positive sentiment.
The outlook is positive with a consensus price target of $70.27, indicating potential upside. Risks include rising interest rate sensitivity and competitive pressures. Earnings growth and dividend stability support a favorable investment case, though macroeconomic factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
